Related Experiment Video
Updated: May 23, 2026
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles
Sally J Deeb1, Rochelle C J D'Souza, Jürgen Cox
1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, D-82152 Martinsried, Germany.
Molecular & Cellular Proteomics : MCP
|March 24, 2012
Summary
Quantitative proteomics accurately distinguishes diffuse large B-cell lymphoma (DLBCL) subtypes. This method identifies key proteins, offering a promising approach for cancer classification and treatment.
Area of Science:
- Proteomics
- Cancer Biology
- Biomarker Discovery
Background:
- Accurate cancer subtyping is crucial for effective diagnosis and treatment.
- Histological assessment is the current standard, but gene expression analysis shows promise.
- Distinguishing between diffuse large B-cell lymphoma (DLBCL) subtypes, activated B-cell-like (ABC) and germinal-center B-cell-like (GCB), is challenging due to histological similarities.
Purpose of the Study:
- To demonstrate the utility of high-accuracy quantitative proteomics for robustly classifying cancer subtypes.
- To investigate the proteomic differences between ABC-DLBCL and GCB-DLBCL subtypes.
- To identify a proteomic signature for differentiating these DLBCL subtypes.
Main Methods:
- Development of a lymphoma-specific stable isotope labeling with amino acids in cell culture (SILAC) mix (super-SILAC).
- Shotgun proteomic analysis using a linear ion trap Orbitrap mass spectrometer on cell lysates from five ABC-DLBCL and five GCB-DLBCL cell lines.
- Principal component analysis (PCA) for subtype segregation based on high-accuracy quantitative proteomic data.
Main Results:
- Identification of over 7,500 proteins with high-accuracy quantification.
- Robust separation of ABC-DLBCL and GCB-DLBCL subtypes via PCA.
- Identification of known differentially expressed proteins (e.g., IRF4, SPI1/PU.1, CD44, CD27) and novel candidates.
- Extraction of a 55-protein signature that segregated subtypes and highlighted functional differences, including NF-κB-regulated genes.
- Successful differentiation of subtypes even with shortened analysis time on a Q Exactive analyzer.
Conclusions:
- High-resolution shotgun proteomics combined with super-SILAC quantification is a powerful tool for tumor characterization.
- This proteomic approach offers a promising alternative or adjunct to current methods for cancer subtyping.
- The identified protein signature provides insights into the functional distinctions between DLBCL subtypes and can aid in diagnosis and treatment strategies.
